What is PHAT stock price today?

Visit our real-time dashboard for the current PHAT stock price and live market data.

Is PHAT stock going up or down today?

PHAT stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy PHAT stock now?

The decision to buy PHAT depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is PHAT a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for PHAT based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is PHAT stock overvalued or undervalued?

Use our DCF valuation calculator to determine if PHAT is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is PHAT's P/E ratio?

P/E ratio data for PHAT will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is PHAT's market cap?

PHAT (Phathom Pharmaceuticals Inc) has a market capitalization of $0.62 billion, making it a small-cap stock.

What is PHAT's price to book ratio?

Price-to-book ratio for PHAT is available on our dashboard along with other valuation metrics.

Does PHAT pay dividends?

PHAT does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is PHAT's dividend yield?

PHAT does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is PHAT stock a good long-term investment?

PHAT's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is PHAT's revenue growth rate?

Revenue growth data for PHAT is available on our dashboard with detailed financial statement analysis.

Profitability metrics for PHAT are available on our dashboard with complete income statement analysis.

What are the risks of investing in PHAT?

Key risks for PHAT include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does PHAT compare to its competitors?

Compare PHAT to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize PHAT's performance and positioning.

What is PHAT's stock price target for 2026?

Visit our prediction page for AI-powered price targets for PHAT with bull, base, and bear case scenarios.

What do analysts say about PHAT?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for PHAT. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is PHAT's next earnings report?

PHAT reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

PHAT - Phathom Pharmaceuticals Inc

NYSE * Healthcare * Biotechnology

$0.00

+$0.00 (+0.00%)

About Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc (PHAT) common stock

Price Chart

Loading chart...

PHAT Key Statistics

Market Cap

$622.74M

How PHAT Compares to Peers

PHAT is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 0

Growth Rank

N/A

of 0

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
PHAT(This stock)	$622.74M	N/A	0%	0.0%	-
AMGNAmgen Inc	$188.67B	24.3	0%	0.0%	vs AMGN
GILDGilead Sciences	$160.15B	17.5	0%	0.0%	vs GILD
VRTXVertex Pharmaceuticals	$106.87B	29.7	0%	0.0%	vs VRTX
REGNRegeneron Pharmaceuticals	$59.10B	13.9	0%	0.0%	vs REGN
BIIBBiogen Inc	$29.33B	21.4	0%	0.0%	vs BIIB

Data Updated: July 17, 2026 at 12:26 AM EDT

Ready to invest in PHAT?

Commission-free trading available. Affiliate links.

PHAT Lician Score

5% confidence

6.0/10

Good

PHAT has a Lician Score of 6/10 (Good). Strengths: Growth.

value

5.0

growth

8.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates PHATacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

PHAT Financial Snowflake

5-axis analysis across key investment dimensions

5.6/10

Neutral

5.0

Value

Valuation vs. sector peers

8.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for PHAT

Dashboard

Enter a ticker to analyze